High-dose IL2 in metastatic melanoma: Better survival in patients immunized with antigens from autologous tumor cell lines

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 2, 2014, Pages 53-57

  Dillman, Robert O ^a,b,c   Depriest, Carol ^c   Mcclure, Stephanie E ^a,b  

^a Hoag Institute for Research and Education   (United States)

^b Hoag Family Cancer Institute   (United States)

^c Cancer Biotherapy Research Group   (United States)

Author keywords

active specific immunotherapy; cancer stem cells; dendritic cells; IL2; melanoma; vaccines

Indexed keywords

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TUMOR; COHORT STUDIES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84894043850     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1565     Document Type: Article

References (32)

1. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (.2010);363:809.
2. Chapman PB, Hauschild, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (.2011);364:2507.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (.2012);366:707.
4. Ascierto PA,Minor D, Ribas A, et al. Phase II Trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (.2013);31:3205.
5. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (.2010);367:1694.
6. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (.2010);367:107.
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (.2010);363:711.
8. Robert C, Thomas LO, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated melanoma. N Engl J Med (.2011);364:26.
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (.2012);366:2443.
10. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med (.2013);369:134.
11. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (.2012);366:2455.
12. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (.1999);17:2105.
13. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: An overview. Oncology (.2009);23:488.
14. Dillman RO, Barth NM, VanderMolen LA, et al. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm (.2012);27:337.
15. Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (.2011);364:2119.
16. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother (.1993);14:65.
17. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous infusion interleukin-2 in 788 patients with cancer: The National Biotherapy Study Group experience. Cancer (.1993);71:2358.
18. Dillman RO, Wiemann MC, VanderMolen LA, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: A phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm (.1997);12:249.
19. Dillman RO, DePriest C, DeLeon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm (.2007);22:309.
20. Dillman RO, Selvan SR, Schiltz PM, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-Tumor vaccines in patients with metastatic melanoma: Final Report. Cancer Biother Radiopharm (.2009); 24:311.
21. Dillman RO, Cornforth AN, Depriest C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: A randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother (.2012);35:641.
22. Selvan SR, Carbonell DJ, Fowler AW, et al. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res (.2010);20:280.
23. Dillman RO, Nanci AA, Williams ST, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm (.2010);25:553.
24. Dillman RO, O'Connor AA, Simpson L, et al. Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol (.2003);26:141.
25. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (.2009);27:6199
26. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-Term survival update. Cancer J Sci Am (.2000);6(suppl 1):S11.
27. Joseph RW, Sullivan R, Harrell R, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (.2012); 35:66.
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (.1998);4:321.
29. Sosman JA, Carrillo C, Urba WJ, et al. Three phase II Cytokine Working Group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HAL-A2-positive advanced melanoma. J Clin Oncol (.2008);26:2292.
30. Dillman RO. Melanoma vaccines: Trials and tribulations. Vaccine Dev Ther (.2013);3:57.
31. Dillman RO, Cornforth AN, Nistor G. Cancer stem cell antigen-based vaccines: The preferred strategy for active specific immunotherapy of metastatic melanoma? Expert Opin Biol Ther (.2013);13:643.
32. Mitchell MS, Jakowatz J, Harel W, et al. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol (.1994);12:402.